Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MITF | O75030 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4788666 | 0.84 | CREBBP (0.51) | CREBBPMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4787096 | 0.80 | KMT2A (0.39) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL15081340 | 0.77 | CREBBP (0.43) | CREBBPMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL27227902 | 0.74 | CREBBP (0.46) | CREBBPMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL15081229 | 0.72 | CREBBP (0.39) | CREBBPMAPTALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL14272018 | 0.71 | CREBBP (0.75) | CREBBPMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL1863124 | 0.69 | CREBBP (0.42) | CREBBPALDH1A1SMN1; SMN2CYP1A2LMNA | |
| SCHEMBL17548191 | 0.68 | AGBL2 (0.43) | MAPTALDH1A1SMN1; SMN2MITFLMNA | |
| SCHEMBL30860870 | 0.68 | CREBBP (0.38) | CREBBPALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8656016 | 0.68 | ALDH1A1 (0.47) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427436-B1 | SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2013-01-09 | — | — | EP | disclosed |
| US-8334315-B2 | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110003795-A1 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| WO-2010127855-A1 | SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2010-11-11 | — | — | WO | disclosed |
| WO-2008110863-A1 | INDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003795-A1 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands | TRPV1, UTS2R, CNR2 | CREBBP 500/4885MAPT 1641/4885ALDH1A1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.